What Uptravi Treats: Main Uses and Benefits

Uptravi is applied in the long-term symptomatic management of Pulmonary Arterial Hypertension (PAH), specifically the WHO Group 1 classification. This therapeutic domain includes idiopathic, heritable, and associated conditions, such as PAH related to connective tissue disorders. The therapeutic use aligns with guidelines for adult patients whose symptoms fall into WHO Functional Class II or Functional Class III, indicating a degree of physical limitation. The support provided may assist with maintaining functional stability in the context of this progressive condition.

A key benefit is supporting the patient during conditions marked by increased physiological stress. The medication is used to manage symptoms like shortness of breath and fatigue that interfere with daily routine. Its role is primarily to help in the management of disease progression and may assist with a reduction in the risk of PAH-related hospitalization. It is commonly applied in scenarios where additional symptomatic support is needed, often as a relevant component of combination therapy regimens.

---

Quick Fact: Support for Symptoms of Physical Limitation The medication supports patients in managing functional symptoms associated with WHO Functional Class II and III PAH, and may contribute to easing the overall symptom load during symptomatic periods.

Uptravi (selexipag) is not for everyone. Official government regulatory documents define specific populations who must avoid this medicine.

Contraindicated Populations

• Strong CYP2C8 Inhibitors: Use of Uptravi is contraindicated (must not be used) in patients who are taking strong inhibitors of the CYP2C8 enzyme, such as gemfibrozil. Co-administration significantly increases the drug's concentration in the body.
• Hypersensitivity: It is contraindicated for any individual with a known allergy or severe sensitivity to selexipag or any of its non-active ingredients.
• Severe Liver Impairment: Use must be avoided in patients with severe hepatic impairment (Child-Pugh Class C). Patients with moderate hepatic impairment (Child-Pugh Class B) require a modified once-daily starting dose.

---

Eligibility Restrictions and Special Considerations

• Cardiovascular Conditions (EMA): European labeling contraindicates use in patients with a history of specific severe cardiac events, including myocardial infarction (heart attack) within the last six months, severe arrhythmias, or certain valvular defects.
• Pediatric Use: The safety and effectiveness of Uptravi in children have not been established. Its administration in the pediatric population is generally not recommended.
• Pregnancy and Lactation: There are no adequate studies in pregnant women. Nursing mothers must either discontinue the drug or discontinue breastfeeding.

Contraindicated and Exposure-Altering Combinations

Uptravi's official interaction profile is defined primarily by pharmacokinetic (PK) constraints related to the drug-metabolizing enzyme Cytochrome P450 2C8 (CYP2C8). The most stringent restriction is the formal contraindication against the co-administration of strong inhibitors of CYP2C8, such as Gemfibrozil.

This restriction is mandated because strong CYP2C8 inhibition is documented in regulatory sources to significantly increase the systemic exposure of the active metabolite (ACT-333679) by approximately 11-fold.

Moderate CYP2C8 Inhibitors and Inducers: Co-administration with moderate inhibitors of CYP2C8 (e.g., Clopidogrel, Deferasirox) results in a documented increase in active metabolite exposure, which requires an administrative constraint on the total daily amount. Conversely, co-administration with strong enzyme inducers (e.g., Rifampin), which affect both CYP2C8 and UGT enzymes, causes a regulatory-noted substantial reduction in active metabolite exposure, also requiring a corresponding administrative constraint.

Other Interaction Constraints: A pharmacodynamic interaction is noted with other vasodilators and hypotensive medications, which may lead to a risk of additive lowering of blood pressure. Furthermore, use is formally avoided in patients with severe hepatic impairment (Child-Pugh class C) due to the condition itself creating a severe population-specific exposure risk.

Selective Activation of the IP Prostacyclin Receptor

This mechanism centers on the active molecule ACT-333679 selectively binding to and stimulating the mathbfIP Receptor on the pulmonary arterial smooth muscle cells. This molecular action provides the functional input of the natural signaling mediator, initiating a cascade that significantly elevates the intracellular messenger Cyclic Adenosine Monophosphate ( cAMP) within the smooth muscle cells.

Dual Action: Vasodilation and Vascular Remodeling Modulation

The surge in cAMP produces a dual physiological effect: it mediates relaxation of smooth muscle cells (vasodilation), and simultaneously limits smooth muscle cell proliferation and extracellular matrix synthesis. These combined actions result in a reduction in Pulmonary Vascular Resistance ( PVR) and mediate a limiting effect on progressive structural changes.

Prodrug Strategy for High Affinity Agonism

The parent compound, Selexipag, functions as an inactive prodrug that is rapidly converted by the enzyme Carboxylesterase 1 ( CES1) into the principal therapeutic agent, ACT-333679. This conversion ensures a high affinity, selective agonistic effect by the active metabolite at the target receptor, leading to the engagement of the cAMP pathway that underlies the drug’s physiological mechanism.

The administration of Uptravi (selexipag) follows a precise, individualized protocol, focusing on both the oral tablet and an intravenous infusion. The oral form is intended for long-term use and is initiated at a starting dose of 200 mcg twice daily (BID). The dose is then gradually increased, or titrated, in 200 mcg BID increments, typically at weekly intervals, until the patient reaches the highest dose they can tolerate, up to a maximum of 1600 mcg BID.

For proper intake, the tablets must be swallowed whole with water and should not be split, crushed, or chewed. Taking the medication with food may assist with tolerability. The intravenous route is reserved for patients who are temporarily unable to take the oral tablets. When administered intravenously, the dose is given as an 80-minute infusion, twice daily, and the dose corresponds to the current stable oral dose.

Specific procedural rules exist for dosing adjustments. If treatment is interrupted for three or more consecutive days, the medication is restarted at a lower dose and the titration process must be repeated. For patients with moderate hepatic impairment (Child-Pugh B), the starting dose and titration increments are reduced. However, no change in the starting dose is required for patients with non-severe renal impairment.

Research Evidence / Overview of Studies for Uptravi

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The main research foundation for selexipag focuses on its use for adults diagnosed with Pulmonary Arterial Hypertension (PAH), which is a condition marked by functional limitations. Selexipag was evaluated in a large, long-term, randomized controlled trial (RCT) that compared the treatment with a placebo. Researchers monitored a primary composite morbidity/mortality outcome, which included the time until a patient experienced a major event related to their PAH, such as a hospitalization for worsening of the condition.

Research examined both newly diagnosed patients and those who were already taking other oral PAH therapies. The findings describe patterns observed in the studies where the primary endpoint measured recorded events such as hospitalization for PAH worsening and disease progression. At Week 26, the research reported a difference in the physical function measure (6MWD) of approximately 12 meters between the selexipag group and the placebo group.

Research Context: Use in Combination Therapy

Selexipag was studied for use both as a monotherapy and when added to one or two existing oral PAH medications. Post-hoc and subgroup analyses from the main trial reported that the study measurement for the composite outcome was explored across patients, regardless of whether they were on single or dual background therapy at the start of the study. Research explored the use of selexipag as part of an initial triple combination regimen, where studies monitored changes in hemodynamic parameters (such as pulmonary vascular resistance).

Functional Measures and Real-World Endpoints

Research examined various outcomes reflecting daily functioning and activity level, including the 6-Minute Walk Distance (6MWD). Research highlights that the change measured in the 6MWD in the main trial was small. Regulatory authorities noted that this measured difference was below the minimal change generally recognized as clinically important. Research also monitored changes in the patient’s WHO Functional Class; however, the patterns observed for this specific secondary endpoint were limited during the main trial.

What Remains Uncertain in the Research

Research is ongoing, but some aspects of the study treatment's use are not fully established. The primary evidence relies on a composite outcome, making the isolated impact on individual events less certain than the composite as a whole. Research indicates that the change measured in key functional outcomes was small, and its clinical significance is limited according to some expert assessments. Finally, long-term effects are not fully established beyond the observed follow-up periods reported in the existing trials.

Key Studies & References Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (GRIPHON) - ClinicalTrials.gov (NCT01106014)

Common questions about Uptravi (FAQ)

---

Q: How is Uptravi different from a traditional prostanoid, since it is described as a 'non-prostanoid'?

A: Uptravi is classified as a non-prostanoid molecule. Regulatory documents state that it is designed to selectively activate only the IP (prostacyclin) receptor, which is one type of receptor in the body. This high selectivity contrasts with how traditional prostanoids work, as they may be associated with a wider range of effects due to less receptor selectivity.

Q: Are there any severe side effects associated with Uptravi that people should know about?

A: Official labeling includes warnings about severe reactions such as signs of a serious allergy, or the development of pulmonary edema (fluid in the lungs) if the patient has a specific condition called Pulmonary Veno-Occlusive Disease (PVOD). Official guidance indicates that these symptoms may require immediate medical attention.

Q: Is Uptravi treatment appropriate for people who are pregnant, planning to become pregnant, or breastfeeding?

A: According to official product information, there are limited data on the use of Uptravi in pregnant women. Patients who may become pregnant are advised in regulatory documents to use effective contraception during treatment. Breastfeeding is not recommended because it is unknown if the drug passes into human milk.

Q: Has Uptravi been studied in children or pediatric patients, and what do the results show?

A: Official regulatory documents indicate that the safety and effectiveness of Uptravi have not been established in children under 18 years of age. Therefore, the safety and efficacy are not established for use in this population.

Q: Can Uptravi be taken with other PAH-specific therapies (e.g., ERAs or PDE-5 inhibitors)?

A: Studies and official information indicate that Uptravi's effectiveness was established in clinical trials where patients were either newly treated or were already taking one or two other oral PAH-specific medications. The research evidence describes its use as part of a combination therapy plan.

Q: What types of over-the-counter medicines or supplements might interact with Uptravi?

A: The regulatory labeling warns that Uptravi may interact with other prescription or over-the-counter medicines, vitamins, or herbal supplements. It is essential for patients to inform their healthcare provider of all products being used, as some may affect how the body processes Uptravi.

Q: What is the typical time frame for the dose adjustment phase to be completed?

A: The initial dose adjustment, or titration phase, is highly individualized. In the main clinical trial, this phase was planned to span the first 12 weeks of treatment. Real-world data indicates the median duration for titration to the individualized maintenance dose was approximately 8 to 12 weeks.

Q: What happens if a patient stops taking Uptravi for several days?

A: Official administration instructions state that if treatment is interrupted for three or more consecutive days, the medication should be restarted at a lower dose. Regulatory guidelines state that the titration process should be repeated.

Q: Does Uptravi have an effect on blood pressure or heart rate?

A: As a drug that promotes the widening of blood vessels (vasodilation), it may cause or contribute to low blood pressure (hypotension). A fast or uneven heart rate is noted in warnings as a serious symptom that may require prompt medical attention.

Q: What is the mechanism by which Uptravi widens blood vessels in the lungs?

A: Uptravi's active metabolite works by targeting and activating the IP receptor on the blood vessels in the lungs. This action mimics the body's natural signaling and causes the smooth muscle cells in the arteries to relax and widen (vasodilation).

Q: What if a patient cannot tolerate the side effects during the dose adjustment phase?

A: If a patient cannot tolerate the side effects (adverse reactions) at a current dose, the official recommendation is to reduce the dose to a previously tolerated level. This is done to maintain treatment while managing comfort.

Q: Does Uptravi only work on one pathway in the body, or does it affect multiple systems?

A: Uptravi primarily works by selectively activating the IP receptor in the prostacyclin pathway. However, official information also describes secondary effects, including inhibiting platelet aggregation (part of the clotting process) and suppressing smooth muscle proliferation.

Q: What is the risk of developing a rash while taking Uptravi?

A: Rash is listed as a common side effect of Uptravi. According to data from the main clinical trial, a rash was reported in 12% of patients taking the drug, compared to 5% of patients taking a placebo.

Q: Does the occurrence or severity of side effects typically decrease after the dose adjustment period?

A: Official documents state that certain adverse reactions that reflect the drug's mechanism of action, such as headache or jaw pain, are often more frequent during the titration phase. These effects are usually transient (temporary), and some may become manageable over time.

Q: Are there any special warnings for elderly patients over the age of 75 using Uptravi?

A: No general dose adjustment is officially required for elderly patients. However, regulatory documents advise using the medicine with caution in patients over 75 years of age because there is limited clinical experience in this specific population.

Q: How does a doctor determine the final, long-term dose of Uptravi for a patient?

A: The final, long-term dose, known as the individualized maintenance dose, is determined by gradually increasing the dose over time. This process continues until the patient reaches the highest dose they can tolerate while successfully managing adverse effects.

Q: What are the long-term clinical trial results that support the use of Uptravi?

A: The main long-term clinical trial reported a relative risk reduction of 16.5% for the composite morbidity/mortality endpoint. This endpoint is defined as the time to a major event related to PAH progression or death.

Q: Did the main study (GRIPHON trial) show that Uptravi improves a patient's exercise ability?

A: The main trial, called GRIPHON, measured exercise ability using the 6-Minute Walk Test. After 26 weeks, the average increase in walking distance was approximately 12 meters greater than the placebo group.

Q: What specific type of disease progression did the clinical trials for Uptravi aim to delay?

A: The clinical trials aimed to delay a composite morbidity/mortality endpoint. This composite included serious events such as hospitalization for PAH worsening, the need to start injectable PAH medications, or other measures of disease progression.

Q: Can taking Uptravi cause changes in the body's thyroid-stimulating hormone (TSH) levels?

A: Official warnings note that hyperthyroidism (an overactive thyroid gland) has been reported in a small number of patients. This indicates a potential effect on the thyroid gland, which is responsible for regulating TSH.

Q: Is Uptravi associated with an increased risk of developing anemia or a low red blood cell count?

A: Anemia (low red blood cell count) is a common side effect of Uptravi. In the main clinical trial, it was reported in 8% of patients taking the drug, compared to 3% in the placebo group, showing an association.

Q: Is it necessary to avoid certain foods or drinks while on Uptravi?

A: Official labeling does not mandate specific food or drink avoidance. However, taking the tablets with food is noted as a way to improve tolerability. Patients should always follow instructions provided by their healthcare provider regarding diet or activity.

Q: Can patients who have specific types of congenital heart disease use Uptravi?

A: Uptravi's effectiveness was studied and established in a population of PAH patients who had specific types of congenital heart disease with repaired shunts. This population was included in the main clinical trials.

Q: Is there any research on using Uptravi in patients with PAH classified as WHO Functional Class IV?

A: The main clinical trial (GRIPHON) primarily involved patients in WHO Functional Class II or Class III. As a result, experience and research data involving patients classified as Class IV are limited.

Q: Can Uptravi affect a person's appetite or weight?

A: Decreased appetite is listed in the official documents as a common side effect of the medication. There is no explicit mention in the regulatory labeling of the drug's direct effect on weight.

Q: Does Uptravi have an effect on kidney function?

A: Uptravi is associated with adverse events related to renal disorders, including acute renal failure and increased blood creatinine in a small number of patients, similar to placebo. Caution is advised for those with severe renal impairment.

Q: Is there information on the safety profile of Uptravi specifically in patients with PAH associated with connective tissue disease?

A: Official studies indicate that Uptravi's effectiveness was established in patients with PAH associated with connective tissue disease. This group represented a significant portion (29%) of the population in the main clinical trial.

Q: Can Uptravi cause fluid buildup in the body or lungs?

A: There is an official warning that the use of vasodilators, including Uptravi, may cause or worsen pulmonary edema (fluid in the lungs) in patients with a specific condition called Pulmonary Veno-Occlusive Disease (PVOD). This warning requires caution and monitoring.

Official Storage and Disposal Requirements

The storage requirements for Uptravi (selexipag) are strictly defined by regulatory labeling and depend on the formulation.

Formulation	Required Storage Condition	Key Constraint
Oral Tablets	Store at room temperature, generally below 30 C (86 F).	Do not freeze; protect from light and moisture; keep in original blister.
Injection Vial (Unopened)	Store in a refrigerator at 2 C to 8 C (36 F to 46 F).	Protect from light by storing in the original carton.

Oral tablets must not be split, crushed, or chewed to maintain drug integrity. The prepared intravenous solution must be handled with constant light protection, diluted only in glass containers, and infused within 4 hours of the initial vial puncture. Both formulations must be stored out of the sight and reach of children. Unused medication and the single-use vials must be disposed of in accordance with local regulations or a medication take-back program.